Cancer and Metastasis Reviews

, Volume 20, Issue 1–2, pp 57–61 | Cite as

Intermittent Blood Flow in Solid Tumours – an under-appreciated Source of ‘drug Resistance’

  • Ralph E. Durand

Abstract

As the search for improved anti-cancer drugs continues, new paradigms concerning the reasons for clinical failures in common human solid tumours are also evolving. Classical drug resistance is now perhaps less often invoked to explain lack of treatment efficacy than are newer concepts, including ‘contact resistance’, ‘tumour heterogeneity’, ‘regrowth resistance’, and ‘physiological barriers’ to drug delivery. This commentary will explore the resistance of solid tumours to chemotherapy from yet another, largely ignored perspective: that of tumour-specific fluctuations in blood flow. Transient decreases in blood flow have significant implications for delivery of chemotherapeutic agents, cellular responsiveness to those agents, and the regrowth potential of the surviving tumour cells.

solid tumours blood flow chemotherapy resistance 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Coleman CN: Hypoxia in tumors: A paradigm for the approach to biochemical and physiologic heterogeneity. J Natl Cancer Inst 80: 310–317, 1988Google Scholar
  2. 2.
    Brown JM,Giaccia AJ: Tumour hypoxia: The picture has changed in the 1990s. Int J Radiat Biol 65: 95–102, 1994Google Scholar
  3. 3.
    Gulledge CJ,Dewhirst MW: Tumor oxygenation: A matter of supply and demand. Anticancer Res 16: 741–749, 1996Google Scholar
  4. 4.
    Durand RE,Sham E: The lifetime of hypoxic human tumor cells. Int J Radiat Oncol Biol Phys 42: 711–715, 1998Google Scholar
  5. 5.
    Leunig M,Yuan F,Menger MD,Boucher Y,Goetz AE,Messmer K,Jain RK: Angiogenesis, microvascular architecture, microhemodynamics, and interstitial fluid pressure during early growth of human adenocarcinoma LS174T in SCID mice. Cancer Res 52: 6553–6560, 1992Google Scholar
  6. 6.
    Denekamp J: Review article: Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol 66: 181–196, 1993Google Scholar
  7. 7.
    Jain RK: Therapeutic implications of tumor physiology. Curr Opinion Oncol 3: 1105–1108, 1991Google Scholar
  8. 8.
    Boucher Y,Lee I,Jain RK: Lack of general correlation between interstitial fluid pressure and oxygen partial pressure in solid tumors. Microvascular Res 50: 175–182, 1995Google Scholar
  9. 9.
    Reinhold HS: In vivo observations of tumor blood flow. In: Peterson HI (ed) Tumor Blood Circulation: Angiogenesis, Vascular Morphology, and Blood Flow of Experimental and Human Tumors, CRC Press, Boca Raton, 1979, pp 115–118Google Scholar
  10. 10.
    Cave AC,Ingwall JS,Friedrich J,Liao R,Saupe KW,Apstein CS,Eberli FR: ATP synthesis during low-flow ischemia: Influence of increased glycolytic substrate. Circulation 101: 2090–2096, 2000Google Scholar
  11. 11.
    Hochachka PW,Buck LT,Doll CJ,Land SC: Unifying theory of hypoxia tolerance: Molecular/metabolic defense and rescue mechanisms for surviving oxygen lack. Proc Natl Acad Sci USA 93: 9493–9498, 1996Google Scholar
  12. 12.
    Hand SC: Quiescence in Artemia franciscana embryos: Reversible arrest of metabolism and gene expression at low oxygen levels. J Exp Biol 201: 1233–1242, 1998Google Scholar
  13. 13.
    Chaplin DJ,Olive PL,Durand RE: Intermittent blood flow in a murine tumor: Radiobiological effects. Cancer Res 47: 597-601, 1987Google Scholar
  14. 14.
    Trotter MJ,Chaplin DJ,Durand RE,Olive PL: The use of fluorescent probes to identify regions of transient perfusion in murine tumors. Int J Radiat Oncol Biol Phys 16: 931–934, 1989Google Scholar
  15. 15.
    Durand RE,LePard NE: Contribution of transient blood flow to tumour hypoxia in mice. Acta Oncol 34: 317–324, 1995Google Scholar
  16. 16.
    Durand RE,LePard NE: Tumour blood flow influences combined radiation and doxorubicin treatments. Radiother Oncol 42: 171–179, 1997Google Scholar
  17. 17.
    Chaplin DJ,Durand RE,Olive PL: Acute hypoxia in tumors: Implications for modifiers of radiation effects. Int J Radiat Oncol Biol Phys 12: 1279–1282, 1986Google Scholar
  18. 18.
    Dewhirst MW,Secomb TW,Ong ET,Hsu R,Gross JF: Determination of local oxygen consumption rates in tumors. Cancer Res 54: 3333–3336, 1994Google Scholar
  19. 19.
    Helmlinger G,Yuan F,Dellian M,Jain RK: Interstitial pH and pO2 gradients in solid tumors in vivo: High-resolution measurements reveal a lack of correlation. Nat Med 3: 177–182, 1997Google Scholar
  20. 20.
    Vaupel P,Schlenger K,Hoeckel M: Blood flow and tissue oxygenation of human tumors: An update. Adv Exp Med Biol 316: 361–371, 1992Google Scholar
  21. 21.
    Brizel DM,Rosner GL,Harrelson J,Prosnitz LR,Dewhirst MW: Pretreatment oxygenation profiles of human soft tissue sarcomas. Int J Radiat Oncol Biol Phys 30: 635–642, 1994Google Scholar
  22. 22.
    Nordsmark M,Overgaard M,Overgaard J: Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 41: 31–39, 1996Google Scholar
  23. 23.
    Aquino-Parsons C,Luo C,Vikse CM,Olive PL: Comparison between the comet assay and the oxygen microelectrode for measurement of tumor hypoxia. Radiother Oncol 51: 179–185, 1999Google Scholar
  24. 24.
    Hill SA,Pigott KH,Saunders MI,Powell ME,Arnold S,Obeid A,Ward G,Leahy M,Hoskin PJ,Chaplin DJ: Microregional blood flow in murine and human tumours assessed using laser Doppler microprobes. Br J Cancer 27: S260–S263, 1996Google Scholar
  25. 25.
    Pigott KH,Hill SA,Chaplin DJ,Saunders MI: Microregional fluctuations in perfusion within human tumours detected using laser Doppler flowmetry. Radiother Oncol 40: 45–50, 1996Google Scholar
  26. 26.
    Kotelnikov VM,Coon JS,Taylor S,Hutchinson J,Panje W,Caldarelli DD,LaFollette S,Preisler HD: In vivo labelling with halogenated pyrimidines of squamous cell carcinomas and adjacent non-involved mucosa of head and neck region. Cell Prolif 28: 497–509, 1995Google Scholar
  27. 27.
    Silvestrini R,Costa A,Veneroni S,Del Bino G,Persici P: Comparative analysis of different approaches to investigate cell kinetics. Cell Tissue Kinet 21: 123–131, 1988Google Scholar
  28. 28.
    Meyer JS: Proliferation assays in prognosis of cancer. J Clin Immunoassay 14: 164–170, 1991Google Scholar
  29. 29.
    Sutherland RM: Cell and environment interactions in tumor microregions: The multicell spheroid model. Science 240: 177–184, 1988Google Scholar
  30. 30.
    Freyer JP: Spheroids in radiobiology. In: Bjerkvig R (ed) Multicell Spheroids, CRC Press, Boca Raton, 1992, pp 217–275Google Scholar
  31. 31.
    Kerbel RS,Rak J,Kobayashi H,Man MS,St Croix B,Graham CH: Multicellular resistance: A new paradigm to expla in aspects of acquired drug resistance of solid tumors. Cold Spring Harbor Sym Quant Biol 59: 661–672, 1994Google Scholar
  32. 32.
    Olive PL,Durand RE: Drug and radiation resistance in spheroids: Cell contact and kinetics. Cancer Metast Rev 13: 121–138, 1994Google Scholar
  33. 33.
    St Croix B,Kerbel RS: Cell adhesion and drug resistance in cancer. Curr Opin Oncol 9: 549–556, 1997Google Scholar
  34. 34.
    Acker H,Carlsson J,Durand RE,Sutherland RM: Spheroids in Cancer Research, Springer-Verlag, Berlin, 1984Google Scholar
  35. 35.
    Cowan DS,Hicks KO,Wilson WR: Multicellular membranes as an in vitro model for extravascular diffusion in tumours. Br J Cancer 74: S28–S31, 1996Google Scholar
  36. 36.
    Minchinton AI,Wendt KR,Clow KA,Fryer KH: Multilayers of cells growing on a permeable support. An in vitro tumour model. Acta Oncol 36: 13–16, 1997Google Scholar
  37. 37.
    Tunggal JK,Melo T,Ballinger JR,Tannock IF: The influence of expression of P-glycoprotein on the penetration of anti-cancer drugs through multicellular layers of solid tissue. Int J Cancer 86: 101–107, 2000Google Scholar
  38. 38.
    Kyle AH,Minchinton AI: Measurement of delivery and metabolism of tirapazamine to tumour tissue using the multilayered cell culture model. Cancer Chemother Pharmacol 43: 213–220, 1999Google Scholar
  39. 39.
    Mendelsohn ML: The growth fraction: A new concept applied to tumors. Science 132: 1496–1496, 1960Google Scholar
  40. 40.
    Meyer JS,He W: Cell proliferation measurements by bromodeoxyuridine or thymidine incorporation: Clinical correlates. Semin Radiat Oncol 3: 135–143, 1993Google Scholar
  41. 41.
    Sham E,Durand RE: Cell kinetics and repopulation parameters of irradiated xenograft tumours in SCID mice: Comparison of two dose-fractionation regimens. Eur J Cancer 35: 850–858, 1999Google Scholar
  42. 42.
    Sham E,Durand RE: Repopulation characteristics and cell kinetic parameters resulting from multi-fraction irradiation of xenograft tumors in SCID mice. Int J Radiat Oncol Biol Phys 43: 617–622, 1999Google Scholar
  43. 43.
    Durand RE: Tumor repopulation during radiotherapy: Quantitation in two xenografted human tumors. Int J Radiat Oncol Biol Phys 39: 803–808, 1997Google Scholar
  44. 44.
    Preisler HD,Venugopal P: Regrowth resistance in cancer: Why has it been largely ignored? Cell Prolif 28: 347–356, 1995Google Scholar
  45. 45.
    Durand RE: Repair and proliferation: Major determinants of the multifraction radiation response. Int J Radiat Oncol Biol Phys 15: 1147–1152, 1988Google Scholar
  46. 46.
    Durand RE,Vanderbyl SL: Tumor resistance to therapy: A genetic or kinetic problem? Cancer Comm 1: 277–283, 1989Google Scholar
  47. 47.
    Durand RE: Cell kinetics and repopulation during multifraction irradiation of spheroids: Implications for clinical radiotherapy. Semin Radiat Oncol 3: 105–114, 1993Google Scholar
  48. 48.
    Durand RE: Multicell spheroids as a model for cell kinetics studies. Cell Tissue Kinet 23: 141–159, 1990Google Scholar
  49. 49.
    Hanahan D,Bergers G,Bergsland E: Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 105: 1045–1047, 2000Google Scholar
  50. 50.
    Klement G,Baruchel S,Rak J,Man S,Clark K,Hicklin DJ,Bohlen P,Kerbel RS: Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105: R15–R24, 2000Google Scholar

Copyright information

© Kluwer Academic Publishers 2001

Authors and Affiliations

  • Ralph E. Durand
    • 1
  1. 1.Department of Medical OncologyUniversity Hospital GroningenThe Netherlands

Personalised recommendations